PIONEERING PROTEINS TO DEFEAT DISEASES

Developing therapeutics to transform patient outcomes with protein engineering and disruptive technology.

At xCella, we are changing the game of protein drug discovery. Our disruptive single-cell xPloration screening technology and proprietary xEmplar human antibody library, combined with our team’s deep expertise in protein engineering and disease biology, are enabling rapid discovery and development of next-generation therapies for patients. 

We are building a pipeline of best-in-class therapeutics against challenging targets in oncology and other disease areas. Our lead molecule XC-201 is a unique clinic-ready asset that harnesses the innate and adaptive immune systems to attack a broad range of tumors.

Our Technologies

Innovative technologies paired with world-class talent accelerate discovery of best-in-class protein therapeutics.